Merck Annual Report 2007 - Development 2003-2007 (optimized for printing)

[ XLS ]

1	In order to harmonize accounting practices, as of 2006 the way in which certain customer rebates in the Pharmaceuticals business sector are reported has been changed.
2	Following its acquisition, the Swiss biopharmaceutical company Serono was integrated with the Ethicals division into Merck Serono.
3	The Generics division was sold in October 2007 and is thus reported as a Discontinued Operation. All revenue, profit and employee figures have been adjusted for 2006 and 2007. The Laboratory Distribution business (VWR) was divested in 2004.

€ million

2003

2004

2005

2006¹

2007²

Change in %

Total revenues

7,343

5,994

5,865

6,284

7,057

Total revenues³(Continuing Operations)

3,559

3,849

4,154

4,460

7,057

Pharmaceuticals³

3,438

3,579

3,885

2,314

4,877

111

Merck Serono²

1,528

1,597

1,797

1,914

4,458

133

Generics³

1,584

1,625

1,712

–

Consumer Health Care

327

357

376

400

420

5.0

Chemicals

1,705

1,694

1,905

2,112

2,150

1.8

Liquid Crystals

443

589

741

895

916

2.3

Performance & Life Science Chemicals

1,082

1,105

1,163

1,217

1,235

1.5

Electronic Chemicals

181

–

Laboratory Distribution³(incl. intragroup sales)

2,199

520

–

Corporate and Other

–

200

–13

Generics³ (Discontinued Operations)

–

1,824

1,395

–

Operating result

736

776

883

1,105

976

–12

Operating result³(Continuing Operations)

512

541

646

799

976

Pharmaceuticals³

389

391

454

217

417

Chemicals

316

420

492

641

631

–1.6

Laboratory Distribution³

–

Corporate and Other

–48

–56

–63

–60

–72

Generics³ (Discontinued Operations)

–

307

189

–

EBITDA³

1,008

1,419

1,245

1,334

1,858

Earnings before interest and tax (EBIT)³

538

1,044

956

1,031

200

–81

Profit before tax³

423

961

893

982

–111

–

Profit after tax (incl. Generics)

218

672

673

1,001

3,520

252

Free cash flow (incl. Generics)

442

1,889

657

–1,073

–1,473

Capital expenditure on property, plant and equipment (incl. Generics)

281

234

268

253

283

Research and development³

605

599

713

615

1,028

Total assets

6,982

5,754

7,281

8,102

14,922

Net equity

2,363

2,800

3,329

3,807

8,688

128

Employees (number as of Dec. 31)³

34,206

28,877

29,133

25,531

30,968

Return on sales³ (ROS) in %
(ROS: Operating result/Total revenues)

10.2

13.2

15.3

17.9

13.8

Earnings per share in €

1.15

3.47

3.45

5.15

16.21

–

Dividend per share in €

0.80

0.85

0.90

1.20

One-time bonus per share in €

–

0.20

–

0.15

2.00

–

Business Development 2003-2007